Related by context. All words. (Click for frequent words.) 69 nephrotoxicity 68 cardiac toxicity 66 mitochondrial toxicity 65 thrombotic events 65 systemic toxicity 65 renal toxicity 64 hepatotoxicity 64 mycophenolate mofetil 64 thromboembolic events 64 TNF antagonist 64 platelet inhibition 64 Toxicities 64 fulvestrant 63 hepatic toxicity 63 intensive statin therapy 63 pharmacokinetic interactions 63 androgen deprivation 63 relapsed ovarian cancer 63 hematological toxicity 63 cediranib 63 invasive candidiasis 63 prostate cancer CaP 63 bevacizumab Avastin 63 thrombotic complications 62 fluvastatin 62 teriflunomide 62 recurrent VTE 62 Dasatinib 62 sorafenib Nexavar 62 hemorrhagic complications 62 antitumor effect 62 docetaxel chemotherapy 62 postoperative mortality 62 disease progression 62 prolongs survival 62 hematopoietic cancers 62 hematologic toxicity 62 nonmelanoma skin cancers 62 sunitinib 62 mTOR inhibitors 62 cytotoxic chemotherapy 62 rebleeding 62 Doxil ® 62 toxicity 62 leukemia AML 62 antiplatelet therapies 62 pertuzumab 62 riociguat 62 chemopreventive agent 62 imatinib therapy 62 locoregional recurrence 62 STRIDE PD 61 radiation sensitizer 61 cisplatin chemotherapy 61 upper gastrointestinal bleeding 61 cardiovascular morbidity 61 catheter angiography 61 recurrent venous thromboembolism 61 mapatumumab 61 endometrial carcinoma 61 perioperative morbidity 61 Hydroxyurea 61 temsirolimus 61 amifostine 61 refractory gout 61 postoperative AF 61 adrenal suppression 61 docetaxel Taxotere ® 61 endometrial hyperplasia 61 hyperbilirubinemia 61 Vidofludimus 61 antidiabetic drugs 61 Adjuvant chemotherapy 61 metastatic kidney 61 chemoradiotherapy 61 androgen suppression 61 ON #.Na 61 cabazitaxel 61 Torsades de Pointes 61 enzastaurin 61 antiandrogens 61 axitinib 61 virologic response 61 polyp recurrence 61 Tyrima 61 antithrombotic therapy 61 antitumor efficacy 61 curative therapy 61 grade glioma 61 Azedra 61 imatinib Gleevec 60 perioperative complications 60 fondaparinux 60 intravenous bisphosphonates 60 mRCC 60 warfarin therapy 60 toxicities 60 elotuzumab 60 dexrazoxane 60 β blockers 60 skeletal metastases 60 neurodevelopmental outcome 60 hyperkalemia 60 PEGylated interferon beta 1a 60 HIV HCV coinfected 60 MYCN amplification 60 metastatic RCC 60 medically inoperable 60 acute leukemias 60 bone marrow suppression 60 iniparib 60 bezafibrate 60 gemcitabine Gemzar 60 chemoresistance 60 standard chemotherapy regimen 60 EGFR inhibitors 60 posaconazole 60 proteasome inhibitors 60 variceal bleeding 60 Akt activation 60 micafungin 60 beta blocker therapy 60 squamous cell lung cancer 60 haematological toxicity 60 Restenosis 60 IV bisphosphonates 60 chlorambucil 60 colorectal carcinoma 60 nucleoside analogues 60 HER2 overexpression 60 clazosentan 60 non squamous NSCLC 60 GnRH agonists 60 intravascular hemolysis 60 direct thrombin inhibitors 60 venous thromboembolic events 60 Asentar 60 erlotinib Tarceva 60 pulmonary toxicity 60 dosing frequency 60 prostate cancer PCa 60 K ras mutations 60 cranial irradiation 60 cardiotoxic 60 ximelagatran 60 symptomatic intracranial hemorrhage 60 pCR 60 Rasilez Tekturna 60 Subgroup analysis 60 cobiprostone 59 angiotensin receptor blockers 59 thromboembolism 59 Procoralan 59 COPD exacerbations 59 alteplase 59 antithrombotics 59 precursor lesions 59 colorectal adenoma 59 delayed CINV 59 pimecrolimus 59 chronic thromboembolic pulmonary 59 Amrubicin 59 statin medications 59 imatinib resistance 59 hypercalcemia 59 platelet inhibitor 59 vandetanib 59 Stent thrombosis 59 figitumumab 59 alkylating agent 59 anti angiogenic agents 59 tolvaptan 59 erlotinib Tarceva ® 59 azacitidine 59 panitumumab Vectibix 59 rFVIIa 59 HuLuc# 59 liver toxicity 59 pegylated interferons 59 lipid lowering therapies 59 DFMO 59 bleomycin 59 VEGF inhibitors 59 Erythropoietic therapies may 59 cerebral ischemia 59 PNH patients 59 SCCHN 59 grade cervical intraepithelial 59 TTF Therapy 59 leukoencephalopathy 59 bevacizumab Avastin ® 59 interferon IFN 59 pegylated liposomal doxorubicin 59 glucose abnormalities 59 postoperative atrial fibrillation 59 valvulopathy 59 adjuvant radiotherapy 59 overlapping toxicities 59 serum phosphate 59 potentially hepatotoxic 59 paricalcitol 59 tigecycline 59 distant metastasis 59 supine hypertension 59 relapsed SCLC 59 Bezielle 59 epithelial tumors 59 operable breast cancer 59 AA Amyloidosis 59 androgen ablation 59 antigen PSA levels 59 malignancies 59 serum calcium levels 59 systolic hypertension 59 reperfusion injury 59 glomerular filtration 59 anthracyclines 59 Erlotinib 59 LHRH agonists 59 CYT# potent vascular disrupting 59 aromatase inhibitors AIs 59 anti leukemic 59 CMV infection 59 pelvic lymphadenectomy 59 recurrent miscarriage 59 invasive aspergillosis 59 metastatic neuroendocrine tumors 59 deferiprone 59 salmeterol HFA MDI 59 taxane chemotherapy 59 HMG CoA reductase inhibitors 59 antiangiogenic activity 59 samalizumab 59 Alessandro Riva 59 cardiac repolarization 59 HNSCC 59 colorectal tumors 59 NATRECOR ® 59 corticosteroid dexamethasone 59 platelet reactivity 59 metastatic renal cell carcinoma 59 myopathy rhabdomyolysis 59 adalimumab Humira 59 glycated hemoglobin levels 59 TG# [003] 59 hyperprolactinemia 59 Bevacizumab 59 dopaminergic therapy 59 MGd 59 malignant ascites 59 gefitinib Iressa 59 Tavocept 59 CTAP# Capsules 59 postoperative delirium 59 atacicept 58 Aplidin 58 eprotirome 58 nonpharmacologic 58 dasatinib Sprycel 58 antitumor activity 58 idarubicin 58 DACH platinum 58 angiographic restenosis 58 antiarrhythmic drugs 58 cardiac dysfunction 58 coadministration 58 anti androgen 58 CETP inhibition 58 antiangiogenic therapy 58 calcineurin inhibitors 58 colorectal neoplasia 58 virologic failure 58 adjuvant therapies 58 myelofibrosis polycythemia vera 58 lapatinib Tykerb 58 Trastuzumab 58 microvascular complications 58 lactic acidosis 58 Aliskiren 58 homozygous familial hypercholesterolemia 58 Afatinib 58 tumor recurrence 58 lipid abnormalities 58 serous ovarian cancer 58 FASLODEX 58 carotid IMT 58 clinically insignificant 58 acute GvHD 58 antiplatelet agent 58 decitabine 58 insulin sensitizers 58 oral anticoagulation 58 gastrointestinal toxicity 58 recurrent DVT 58 bone metastasis 58 neurotoxicity 58 thromboembolic complications 58 antiangiogenic agent 58 oncologic outcomes 58 trimethoprim sulfamethoxazole 58 macrovascular events 58 reinfarction 58 EGFR tyrosine kinase inhibitors 58 angiogenesis inhibition 58 lupus nephritis 58 Lp PLA2 58 antiarrhythmic 58 Cloretazine 58 cardiovascular hospitalization 58 MS relapses 58 nephrotoxic 58 trastuzumab Herceptin ® 58 fibrinolytic 58 torsades de pointes 58 tocilizumab 58 renal dysfunction 58 vinorelbine 58 sotalol 58 basiliximab 58 TORISEL 58 antiplatelet therapy 58 prostate cancer CRPC 58 olaparib 58 myocardial ischemia 58 insulin sensitizing 58 contrast induced nephropathy 58 cytotoxicity 58 Xelox 58 GRNCM1 58 CTEPH 58 post surgical adhesions 58 glitazones 58 AEG# 58 tumorigenicity 58 neurologic progression 58 nilotinib 58 corrected QT interval 58 conventional antipsychotics 58 galiximab 58 masitinib 58 atrial arrhythmias 58 anthracycline therapy 58 anticancer therapy 58 bexarotene 58 ribavirin therapy 58 Noxafil 58 Darapladib 58 BAY #-# 58 antigen PSA 58 QT interval prolongation 58 colorectal liver metastases 58 teratogenic 58 prognostic marker 58 MAGE A3 ASCI 58 severe exacerbations 58 paroxetine Paxil 58 myelosuppression 58 Golimumab 58 metaglidasen 58 MALT lymphoma 58 myelodysplastic syndromes MDS 58 idraparinux 58 Adalimumab 58 Taxotere chemotherapy 58 Sorafenib 58 BANZEL 58 autoimmune reactions 58 immunosuppressive regimens 58 ISTODAX 58 thienopyridines 58 angiotensin converting enzyme inhibitors 58 TNFa 58 cardiac troponin 58 postoperative morbidity 58 pharmacologic intervention 58 CMV disease 58 QTc prolongation 58 nocturnal hypoglycaemia 58 doxorubicin HCl 58 platelet activation 58 gemifloxacin 58 Telintra 58 decompensated cirrhosis 58 OXi# 58 cetuximab Erbitux 58 EXJADE 58 Myelofibrosis 58 Aprotinin 58 SHPT 58 somatostatin analogs 58 cilengitide 58 Pemetrexed 58 Bosentan 58 PRT# 58 cystatin C 58 NNRTIs 58 metastatic gastric 58 TroVax ® 58 Gleevec resistant 58 pomalidomide 58 intracranial hemorrhage ICH 58 demonstrated antitumor activity 58 antioxidant supplementation 58 clodronate 58 cirrhotic patients 58 VEGF expression 58 PTLD 58 B7 H3 57 QT prolongation 57 corticosteroid therapy 57 pyridostigmine 57 atypical antipsychotic medications 57 intracranial stenosis 57 pancreatic adenocarcinoma 57 transaminase elevations 57 coronary stenosis 57 abdominal adiposity 57 tolerability profiles 57 Zolinza 57 EGFR TKIs 57 prognostically 57 immunosuppressive regimen 57 histone deacetylase inhibitor 57 heterozygous FH 57 prognostic indicator 57 Pseudomonas aeruginosa infections 57 topotecan 57 angiogenesis inhibitor 57 transgene expression 57 myeloproliferative disorders 57 mammary tumors 57 serum PSA 57 non metastatic osteosarcoma 57 hepatorenal syndrome 57 PDE4 inhibitors 57 ABCB1 57 antianginal 57 Hurthle cell 57 cytotoxic therapy 57 Irinotecan 57 deletion 5q 57 plasma pharmacokinetics 57 hydroxyurea 57 QTc interval 57 LHRH antagonists 57 pheochromocytoma 57 TACE 57 DAPT 57 candidemia 57 efalizumab 57 atherosclerotic lesions 57 CCyR 57 rosuvastatin Crestor 57 extrapyramidal symptoms 57 Anthracycline 57 velafermin 57 durable remissions 57 TNF α 57 Natalizumab 57 SUVmax 57 neutrophil counts 57 Decitabine 57 Zollinger Ellison Syndrome 57 eplerenone 57 Kinoid 57 intracerebral hemorrhage 57 serum urate levels 57 thromboembolic 57 gadobutrol 57 Symadex 57 immunomodulatory therapy 57 hemodilution 57 teratogenicity 57 serum LDL cholesterol 57 motavizumab 57 liver transplant recipients 57 cerebral vasospasm 57 INCB# [003] 57 mixed hyperlipidemia 57 hematologic disorders 57 variceal hemorrhage 57 complement inhibitor eculizumab 57 LY# [003] 57 parkinsonian symptoms 57 virological failure 57 CANCIDAS 57 pediatric malignancies 57 LEP ETU 57 Torisel 57 torsade de pointes 57 AST ALT 57 antihypertensive therapy 57 PI3K inhibitors 57 seliciclib 57 prostate carcinoma 57 symptomatic aortic stenosis 57 F FDG PET 57 atherosclerotic disease 57 Ivabradine 57 anticancer treatments 57 HGS ETR1 57 neurocognitive deficits 57 selective inhibition 57 panobinostat 57 PAOD 57 myocardial reperfusion 57 ACZ# 57 CA4P 57 APTIVUS r 57 ancrod 57 ovarian carcinoma 57 antiproliferative effects 57 combinability 57 PSADT 57 tanespimycin 57 invasive fungal infections 57 trastuzumab DM1 57 recurrent glioblastoma multiforme 57 osteosarcomas 57 Navelbine 57 DMARD 57 infliximab Remicade 57 GvHD 57 bovine thrombin 57 biphosphonates 57 candesartan 57 thalidomide Thalomid 57 varices 57 intravenous dosing 57 thromboembolic disease 57 paroxysmal AF 57 rt PA 57 antiangiogenic agents 57 TNF alpha antagonist 57 vismodegib 57 interferon therapy 57 endothelin receptor antagonists 57 endometrial cancers 57 XELOX 57 schizophrenia CIAS 57 atherothrombotic events 57 hormonal therapies 57 diagnostic biomarker 57 RE LY 57 chemotherapeutic regimens 57 menstrual migraine 57 adecatumumab 57 differentiated thyroid 57 palliative radiotherapy 57 invasive coronary angiography 57 allograft rejection 57 TNF inhibitor 57 brain metastases 57 edifoligide 57 proteasome inhibitor 57 bone metastases 57 darapladib 57 BRAF inhibitor 57 liver metastasis 57 pharmacokinetic characteristics 57 Imatinib 57 Critical Limb Ischemia CLI 57 androgen therapy 57 thrombophilia 57 inhibitor RG# 57 tumor necrosis 57 osteoclast activity 57 hypercholesterolemia 57 malignant pleural mesothelioma 57 urate levels 57 Vidaza azacitidine 57 Seliciclib 57 Neulasta ® 57 intima media thickness 57 morphometric vertebral fractures 57 intravenous cyclophosphamide 57 prognostic indicators 57 cardioprotective effects 57 erythropoietic 57 postoperative chemotherapy 57 visilizumab 57 ganetespib 57 PREZISTA r 57 JAK inhibitor 57 CIMZIA ™ 57 effector function 57 metastatic malignant 57 ciclosporin 57 neurodevelopmental impairment 57 neoadjuvant therapy 57 nonvertebral fractures 57 tyrosine kinase inhibitors TKIs 57 tumor lysis syndrome 57 SERCA2a 57 VA# [002] 57 ELACYT 57 artery stenosis 57 Venous thromboembolism 57 biodistribution 57 castration resistant prostate cancer 57 forodesine 57 chemosensitivity 57 APOPTONE 57 Critical limb ischemia 57 liposomal amphotericin B 57 hyperglycaemia 57 HER2 positive metastatic breast 57 inflammatory biomarkers 57 monoclonal gammopathy 57 unmeasured confounders 57 dacetuzumab 57 PSN# [002] 57 IFN beta 57 FOLFOX4 57 dexpramipexole 57 recurrent myocardial infarction 57 antithrombotic 57 hyperoxaluria 57 adult chronic ITP 57 nonfatal MI 57 Liver transplantation 57 calcitriol 57 histological subtype 57 Mitoxantrone 57 ticagrelor 57 estrogen progestin therapy 57 thrombolytic agents 57 Traficet EN 57 XL# SAR# 57 elinogrel 57 TZDs 57 secondary hyperparathyroidism 57 Non inferiority 57 B CLL 56 microvascular disease 56 ZOLINZA 56 PSMA ADC 56 rituximab Rituxan 56 antiplatelet drugs 56 TMP SMX 56 H. pylori eradication 56 Fludara 56 S/GSK# 56 levosimendan 56 flutamide 56 adenoma recurrence 56 hypoglycemic episodes 56 cardiovascular disease hypertension 56 chlamydial infection 56 MMP inhibitor 56 lung fibrosis 56 IL# PE#QQR 56 curative resection 56 interferon alfa 56 newer atypical antipsychotics 56 symptomatic VTE 56 Hepatocellular Carcinoma HCC 56 bronchopulmonary dysplasia BPD 56 FOLFIRI 56 NV1FGF 56 CIN3 56 severe neutropenia 56 tibolone 56 HbF 56 T2DM 56 Pulmonary hypertension 56 biochemical recurrence 56 Targretin 56 PCa 56 hepatocellular carcinoma 56 gastrointestinal perforation 56 Hypotension 56 TEAEs 56 medullary thyroid cancer 56 Inhaled nitric oxide 56 microtubule targeting 56 CINTREDEKIN BESUDOTOX 56 serum phosphate levels 56 colorectal cancer CRC 56 immunopathology 56 prostate carcinogenesis 56 grade gliomas 56 anidulafungin 56 PRADAXA 56 dasatinib 56 CIPN 56 bosentan 56 gastric carcinoma 56 MMP inhibitors 56 allogeneic transplantation 56 non selective NSAIDs 56 clinically meaningful differences 56 lactate dehydrogenase LDH 56 cytotoxic effects 56 CYP #A# 56 repolarization 56 selegiline 56 advanced adenomas 56 Host Disease GvHD 56 selective NSAIDs 56 NATRECOR R 56 severe hypersensitivity reactions 56 renal flares 56 E selectin 56 anthracycline chemotherapy 56 alvespimycin 56 ADHF 56 breast cancer recurrence 56 protease inhibitor PI 56 tumor subtypes 56 HER2 expression 56 motesanib 56 autoantibody levels 56 atherothrombotic disease 56 cancer mCRC 56 nonadherence 56 irbesartan 56 Aclidinium 56 heparin induced thrombocytopenia 56 myeloproliferative diseases 56 diabetic kidney 56 noncancer 56 haematologic 56 Everolimus 56 colorectal cancer liver metastases 56 alpha blocker 56 conventional angiography 56 breast carcinoma 56 relapsed ALL 56 specific antigen PSA 56 SRBD 56 fetal malformations 56 systemically administered 56 perioperatively 56 sunitinib Sutent 56 urine NGAL 56 nonsmall cell lung cancer 56 QTc intervals 56 pharmacodynamic properties 56 vasogenic edema 56 antiplatelet medications 56 canakinumab 56 Fibrillex TM 56 recurrent ischemia 56 myocardial ischaemia 56 adrenal insufficiency 56 hepatic metastases 56 depsipeptide 56 ritonavir boosting 56 bronchopulmonary dysplasia 56 muraglitazar 56 epithelial ovarian cancer 56 PTP 1B 56 D dimer 56 plasma uric acid 56 Mucositis 56 HER2 positive cancers 56 CP CPPS 56 myeloperoxidase 56 prednisone prednisolone 56 Tumor Necrosis Factor 56 thiopurine 56 VIDAZA 56 GISTs 56 cilostazol 56 docetaxel Taxotere 56 inhibit platelet aggregation 56 glycosylated hemoglobin HbA1c 56 alkylating agents 56 Fludarabine 56 GW# [003] 56 BEACOPP 56 obatoclax 56 indolent NHL 56 venlafaxine Effexor 56 ranolazine 56 Neutropenia 56 chronic lymphocytic leukemia CLL 56 hepatic fibrosis 56 chronic periodontitis 56 Candida infections 56 leukemia ALL 56 chemotherapies 56 Hodgkin lymphoma HL 56 indolent lymphomas 56 tumor histology 56 Angioedema 56 receptor tyrosine kinase inhibitor 56 vivo potency 56 micrometastasis 56 basal cell carcinoma BCC 56 preoperative chemotherapy 56 Gliadel Wafer 56 Gleevec imatinib 56 paclitaxel Taxol ® 56 efaproxiral 56 carcinoid tumors 56 angiotensin receptor blockers ARBs 56 EGFR TKI 56 chemotherapeutic drug 56 arterial thrombosis 56 receptor inhibitor 56 sulfasalazine 56 cervical carcinoma 56 IDH mutations 56 Valsartan 56 relapsed MM 56 stratifying patients 56 aspirin clopidogrel 56 residual confounding 56 viral kinetics 56 murine models 56 acute coronary syndromes ACS 56 HBeAg negative 56 vorinostat 56 TMEM density 56 recurrent atrial fibrillation 56 glufosfamide 56 JAK inhibitors 56 rosiglitazone Avandia 56 IV NSCLC 56 Bivalirudin 56 nesiritide 56 interferon ribavirin 56 Gefitinib 56 primidone 56 antiandrogen 56 neurologic complications 56 acute gout flares 56 Cytoxan 56 antiemetics 56 goserelin 56 glycemia 56 thromboprophylaxis 56 basal cell nevus syndrome 56 mycophenolate mofetil MMF 56 antidepressant efficacy 56 TAXUS Stent 56 abiraterone 56 prognostic factor 56 physiologic mechanisms 56 potency selectivity 56 COX 2s 56 solar keratoses 56 metastatic castration resistant 56 superficial bladder cancer 56 renal insufficiency 56 adverse cytogenetics 56 nonvertebral fracture 56 pain palliation 56 cetuximab Erbitux R 56 portal vein thrombosis 56 flavopiridol 56 immunosuppressive therapies 56 alpha interferons 56 pharmacokinetic properties 56 complete cytogenetic response 56 imatinib Gleevec ® 56 prostate cancer mCRPC 56 cinacalcet 56 NAbs 56 daclizumab 56 gemcitabine carboplatin 56 pimozide 56 endostatin 56 histologic subtype 56 lymphomas leukemias 56 ZACTIMA 56 EOquin TM 56 gastrointestinal stromal tumors GIST 56 digoxin toxicity 56 metabolic acidosis 56 prolonged QT interval 56 acute toxicity 56 vasospasm 56 oral prodrug 56 venous blood clots 56 plasma triglycerides 56 Azixa 56 definite stent thrombosis 56 atherogenic dyslipidemia 56 anticancer therapies 56 eltrombopag 56 chemotherapy induced neutropenia 56 revascularization procedures 56 Nexavar sorafenib 56 AChE inhibitors 56 kidney allograft 56 radiographic progression 56 allogeneic HSCT 56 glioblastoma tumors 56 TREANDA 56 smoldering multiple myeloma 56 atrial tachyarrhythmias 56 amrubicin 56 AAT deficiency 56 HeFH 56 Renal Cell Carcinoma RCC 56 drug zotarolimus 56 noscapine 56 seminoma 56 androgen deprivation therapy 56 XIENCE V PROMUS Stent 56 aspartate aminotransferase 56 aminotransferases 56 Hsp# inhibition 56 impair fertility 56 lenalidomide dexamethasone 56 testosterone supplementation 56 renal carcinoma 56 prostate adenocarcinoma 56 OHR/AVR# 56 EBRT 56 proteasome inhibitor bortezomib 56 Perifosine 56 hypersensitivity reaction 56 uterine tumors 56 Clusterin 56 pan HDAC inhibitor 55 TELINTRA 55 RAPAFLO R 55 atypical hyperplasia 55 cerebral microbleeds 55 ADPKD 55 colorectal neoplasms 55 serum calcium 55 dyslipidemic 55 ReoPro 55 diabetic nephropathy 55 Paxil paroxetine 55 Cremophor 55 HCV infection 55 nucleoside analog 55 locoregional 55 5-FU/LV 55 ticlopidine 55 thrombosis 55 chemoradiation therapy 55 estramustine 55 colon perforation 55 HGS# 55 myeloablative 55 urothelial bladder cancer 55 TT genotype 55 haloperidol Haldol 55 hepatocellular carcinoma HCC 55 atypical femur fractures 55 perioperative mortality 55 detecting colorectal cancer 55 recurrent GBM 55 VAPRISOL 55 chemotherapeutic agents 55 metastatic bone 55 clopidogrel Plavix 55 left ventricular dysfunction 55 microglial activation 55 ICD implantation 55 Actos pioglitazone 55 neuropsychiatric symptoms 55 subclinical atherosclerosis 55 cytoreductive surgery 55 Sym# 55 Zarnestra 55 carotid artery stenting 55 anemia hemoglobin 55 tumor regrowth 55 liposomal doxorubicin 55 ventricular arrhythmias 55 T1DM 55 hepatocellular 55 Certolizumab pegol 55 talabostat 55 node metastases 55 dacarbazine 55 dysglycemia 55 antiviral efficacy 55 oral anticoagulant 55 taxane therapy 55 leiomyomas 55 endocrine therapies 55 colorectal polyps 55 clomipramine 55 androgen receptor AR 55 selenium supplementation 55 metastatic prostate cancer 55 liver fibrosis 55 angiographically 55 familial adenomatous polyposis 55 metastatic bladder 55 Hematologic toxicity 55 noncardiac 55 diabetic gastroparesis 55 fibrotic disease 55 psoriatic arthritis PsA 55 BENICAR HCT 55 chemotherapeutic regimen 55 intraoperative complications 55 ritonavir boosted 55 evaluating tivozanib